These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32372174)

  • 21. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
    Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
    Gastric Cancer; 2024 Jul; 27(4):802-810. PubMed ID: 38724721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
    Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and Content of Protein LC3B in Gastric Cancer Tissue, Relationship with Expression of mTOR, AMPK in Gastric Cancer Tissue and HER2 and PD-L1 Status of the Tumor.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Volkov MY; Kondakova IV
    Bull Exp Biol Med; 2021 Dec; 172(2):202-205. PubMed ID: 34855092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.
    Rong L; Zhao H; Li Y; Jin M; Lu J
    J Clin Pathol; 2024 Mar; 77(4):233-238. PubMed ID: 36650045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
    Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
    Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
    Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
    Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
    Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
    Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
    Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
    Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
    Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
    Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
    Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
    Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
    Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
    Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.